Zoetis Inc. $ZTS Position Boosted by Davis Rea LTD.

Davis Rea LTD. increased its holdings in Zoetis Inc. (NYSE:ZTS) by 10.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,682 shares of the company’s stock after purchasing an additional 4,443 shares during the quarter. Zoetis accounts for 1.6% of Davis Rea LTD.’s holdings, making the stock its 21st biggest position. Davis Rea LTD.’s holdings in Zoetis were worth $6,684,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ZTS. Scott & Selber Inc. lifted its position in shares of Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after acquiring an additional 67 shares during the last quarter. North Star Asset Management Inc. raised its position in shares of Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after purchasing an additional 67 shares during the period. Secure Asset Management LLC lifted its holdings in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after purchasing an additional 68 shares during the last quarter. Moment Partners LLC boosted its position in shares of Zoetis by 3.2% in the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares during the period. Finally, CVA Family Office LLC increased its stake in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after purchasing an additional 74 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ZTS shares. Weiss Ratings upgraded Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a report on Monday, December 15th. UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. KeyCorp began coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Finally, Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a report on Monday, December 15th. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Stock Down 0.4%

ZTS stock opened at $125.32 on Friday. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market cap of $55.23 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 2.56 and a beta of 0.97. The company has a 50 day moving average of $123.12 and a two-hundred day moving average of $139.84.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the previous year, the company posted $1.58 EPS. Zoetis’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.